—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Orion Oyj B (ORNBV.HE) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for ORNBV.HE, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 61/100 · S&P 500 fund at 75, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-06
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 98th percentile of the window, +5.7% over 20 sessions. Factor regime → 2026-10-06
  • Sector × region Health care in Europe: −1.2% week · −3.2% month · −6.1% quarter · +2.3% yearThe Sector Engine cell this name lives in, from EXV4.XETRA; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-10-06
  • Sovereign pressure Index 0.74 · up 0.17 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-06
Who it is priced against Drug Manufacturers - General · 8 names with week and year-to-date

Peer group

Drug Manufacturers - General

Names in the same industry from the Closelooknet universe; scored names rank on their Closelooknet score, the rest on trend state.

Compared against ORNBV.HE on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Orion Oyj B

ORNBV.HE in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Orion Oyj develops, makes and sells human and veterinary medicines together with active pharmaceutical ingredients, headquartered in Espoo, Finland. It sells prescription drugs for prostate cancer, Parkinson's disease, asthma and pain, plus veterinary treatments and self-care products such as supplements and skincare, marketed across Nordic, European and international markets.
Where it sits in the stack
Orion sits outside Rubin, our index tracking the AI build-out; it belongs instead to the wider Healthcare sector, in the Drug Manufacturers - General industry line of our coverage.
Who it is priced against
Closelooknet's peer group for Orion is not defined in our coverage; the market sometimes names Novo Nordisk as a comparator given its Nordic pharmaceutical scale.
Why Closelooknet tracks it
Orion is not a constituent of Rubin or any other Closelooknet index, but it does carry a score, with momentum standing as its most active module; the diary has not yet quoted it in an edition.
What the diary watches
The diary watches whether momentum readings hold as Orion's oncology and respiratory lines meet generic competition and as its licensing agreements, such as the one with Bayer, develop.

Orion Oyj B (ORNBV.HE) trades on the HE exchange in Finland, classified under Healthcare.

The Closelooknet company score reads 62/100 composite (momentum 77, quality 85, valuation 34) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Dividends and capital return trailing yield 2.13%, semi-annual · last 0.91 EUR on 2026-03-02

Dividends and capital return

What ORNBV.HE pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 1.73 EUR per share · a 2.13% yield on the 2026-10-06 close 2 distributions, paid twice a year 2026-10-06
  • Change on the year +110.9% against the prior twelve months prior twelve months 0.82 EUR per share
  • Last distribution 0.91 EUR per share as the price series records it, within days of the ex-date 2026-03-02
  • By calendar year 2025: 1.64 EUR (partial) · 2026: 0.91 EUR to date first distribution recorded in the three-year window: 2025-04-04
  • Dividends paid, FY2025 231 m EUR 63% of earnings
  • Share count +0.1% in FY2025
  • Capital returned 231 m EUR · 105% of free cash flow dividends and buybacks together, against the year’s free cash flow

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-10-07

Quick answers

What is Orion Oyj B (ORNBV.HE)?

Orion Oyj B trades as ORNBV.HE on the HE exchange (Finland) and is classified under Healthcare in the Closelooknet research universe, as of the registry build of 2026-10-07.

Is ORNBV.HE in a Closelooknet index?

Not currently — Orion Oyj B is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-07.

What is Orion Oyj B's Closelooknet composite score?

62 out of 100, with momentum 77, quality 85 and valuation 34 sub-scores, as of 2026-10-07. Scores are Closelooknet's own research readings, not ratings or investment advice.

Where does ORNBV.HE trade against its moving averages?

Uptrend stack intact: Trades +1.1% vs the 50-day and +12.8% vs the 200-day average, 3.8% below the 52-week high and +45.9% off the 52-week low. Computed from daily closes. As of 2026-10-06 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Orion Oyj B compare with its peers?

Against its peer group (Drug Manufacturers - General), Orion Oyj B (ORNBV.HE) sits 3.8% below its 52-week high, 1.1% above its 50-day average; Eli Lilly and Company (LLY) is 11.6% below, Orion Oyj A (ORNAV.HE) is 3.4% below, Amgen Inc (AMGN) is 9.9% below. Put any of them next to ORNBV.HE in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

What does Orion Oyj B do?

Orion Oyj develops, makes and sells human and veterinary medicines together with active pharmaceutical ingredients, headquartered in Espoo, Finland. It sells prescription drugs for prostate cancer, Parkinson's disease, asthma and pain, plus veterinary treatments and self-care products such as supplements and skincare, marketed across Nordic, European and international markets. Closelooknet's peer group for Orion is not defined in our coverage; the market sometimes names Novo Nordisk as a comparator given its Nordic pharmaceutical scale.

Where does Orion Oyj B sit in the AI build-out?

Orion sits outside Rubin, our index tracking the AI build-out; it belongs instead to the wider Healthcare sector, in the Drug Manufacturers - General industry line of our coverage. Orion is not a constituent of Rubin or any other Closelooknet index, but it does carry a score, with momentum standing as its most active module; the diary has not yet quoted it in an edition.

Does Orion Oyj B pay a dividend?

Orion Oyj B has paid 1.73 EUR per share over the last twelve months, paid twice a year, a trailing yield of 2.13% on the 2026-10-06 close; the last distribution recorded in the price series was 0.91 EUR on 2026-03-02. In fiscal 2025 the company paid 231 m EUR in dividends, 105% of that year’s free cash flow. The share count rose 0.1% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for ORNBV.HE, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Drug Manufacturers - General, then Healthcare. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.